ArticleExpert review of molecular diagnostics2011

Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes.

Gerald B Wertheim et al.PubMed ↗Publisher ↗

No numbers read from the abstract.